Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N H Russell

Showing results (81-90 of 156) with videos related to

Pageof 16
Sort By:
British Journal of Rheumatology|December 1, 1988
Abnormal fibrinolytic activity in systemic lupus erythematosus and possible mechanismsP Chu, N H Russell, R J Powell, et al.
British Journal of Haematology|June 26, 2003
Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemiaE Harris, J Behrens, D Samson, et al.
British Journal of Haematology|December 1, 1990
Interleukin-1 is one factor which regulates autocrine production of GM-CSF by the blast cells of acute myeloblastic leukaemiaD Bradbury, S Rogers, R Kozlowski, et al.
Bone Marrow Transplantation|November 18, 1998
Adjuvant alpha-interferon improves complete remission rates following allogeneic transplantation for multiple myelomaJ L Byrne, G I Carter, N Bienz, et al.
Clinical and Laboratory Haematology|June 1, 1994
Intensive treatment of renal failure in patients with myelomaA Innes, R J Cuthbert, N H Russell, et al.
Bone Marrow Transplantation|October 6, 1997
Autologous GVHD following PBSCT, with evidence for a graft-versus-myeloma effectJ L Byrne, G I Carter, I Ellis, et al.
Leukemia Research|February 28, 2007
High dose melphalan or intermediate dose melphalan can be well tolerated and result in good response rates in selected elderly patients with myelomaM Bishton, M Gilyead, E Das Gupta, et al.
Journal of Hematotherapy|September 15, 1998
A comparison of two different systems for CD34+ selection of autologous or allogeneic PBSC collectionsC J Stainer, G Miflin, S Anderson, et al.
British Journal of Haematology|March 21, 2008
IVE (ifosfamide, epirubicin and etoposide) is a more effective stem cell mobilisation regimen than ICE (ifosphamide, carboplatin and etoposide) in the context of salvage therapy for lymphomaC P Fox, A K McMillan, M J Bishton, et al.
British Journal of Haematology|May 8, 1999
Second allogeneic transplant for severe aplastic anaemia following late graft rejectionG Miflin, N H Russell, A Haynes, et al.
Pageof 16

Showing results (81-90 of 156) with videos related to

Sort By:
Pageof 16
British Journal of Rheumatology|December 1, 1988
Abnormal fibrinolytic activity in systemic lupus erythematosus and possible mechanismsP Chu, N H Russell, R J Powell, et al.
British Journal of Haematology|June 26, 2003
Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemiaE Harris, J Behrens, D Samson, et al.
British Journal of Haematology|December 1, 1990
Interleukin-1 is one factor which regulates autocrine production of GM-CSF by the blast cells of acute myeloblastic leukaemiaD Bradbury, S Rogers, R Kozlowski, et al.
Bone Marrow Transplantation|November 18, 1998
Adjuvant alpha-interferon improves complete remission rates following allogeneic transplantation for multiple myelomaJ L Byrne, G I Carter, N Bienz, et al.
Clinical and Laboratory Haematology|June 1, 1994
Intensive treatment of renal failure in patients with myelomaA Innes, R J Cuthbert, N H Russell, et al.
Bone Marrow Transplantation|October 6, 1997
Autologous GVHD following PBSCT, with evidence for a graft-versus-myeloma effectJ L Byrne, G I Carter, I Ellis, et al.
Leukemia Research|February 28, 2007
High dose melphalan or intermediate dose melphalan can be well tolerated and result in good response rates in selected elderly patients with myelomaM Bishton, M Gilyead, E Das Gupta, et al.
Journal of Hematotherapy|September 15, 1998
A comparison of two different systems for CD34+ selection of autologous or allogeneic PBSC collectionsC J Stainer, G Miflin, S Anderson, et al.
British Journal of Haematology|March 21, 2008
IVE (ifosfamide, epirubicin and etoposide) is a more effective stem cell mobilisation regimen than ICE (ifosphamide, carboplatin and etoposide) in the context of salvage therapy for lymphomaC P Fox, A K McMillan, M J Bishton, et al.
British Journal of Haematology|May 8, 1999
Second allogeneic transplant for severe aplastic anaemia following late graft rejectionG Miflin, N H Russell, A Haynes, et al.
Pageof 16